DGIdb - METHYLPHENIDATE Drug Record

METHYLPHENIDATE chembl:CHEMBL796 Approved

Alternate Names:

METHYLIN
CONCERTA
COTEMPLA XR-ODT
DAYTRANA
METHYLPHENIDATE

Drug Info:

Drug Class	central nervous system stimulants
Year of Approval	approved before 1982
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of ADHD
Drug Categories	agents that produce hypertension
Drug Categories	agents that reduce seizure threshold
Drug Categories	central nervous system stimulation
Drug Categories	drugs that are mainly renally excreted
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	methylphenidate and isomer
Drug Categories	respiratory and cns stimulants

(5 More Sources)

Publications:

Pagerols M et al., 2017, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder., Pharmacogenomics J
Pagerols M et al., 2018, Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder., Sci Rep
Myer NM et al., 2018, Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD., Mol Psychiatry
Contini V et al., 2012, No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD., J Clin Psychopharmacol
Park S et al., 2014, Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea., J Psychopharmacol
Kereszturi E et al., 2008, Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children., Am J Med Genet B Neuropsychiatr Genet
Cheon KA et al., 2008, Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder., Int Clin Psychopharmacol
Green T et al., 2011, The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome., J Child Adolesc Psychopharmacol
Yatsuga C et al., 2014, No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children., Brain Dev
Salatino-Oliveira A et al., 2011, Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder., Biol Psychiatry
Izenwasser et al., 1999, Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine., Eur. J. Pharmacol.
Cheon et al., 2005, The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate., Eur Neuropsychopharmacol
Dresel et al., 1999, In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates., Eur J Nucl Med
Viggiano et al., 2004, Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling., Neural Plast.
Volkow et al., 1999, Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain., Life Sci.
Volkow et al., 1999, Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain., Synapse
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Trinh et al., 2003, Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice., Neuroscience
Stein et al., 2005, Dopamine transporter genotype and methylphenidate dose response in children with ADHD., Neuropsychopharmacology
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Wayment et al., 1999, Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists?, J. Neurochem.
Berridge CW et al., 2006, Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function., Biol Psychiatry
Tilley et al., 2008, The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter., J. Pharmacol. Exp. Ther.
Markowitz JS et al., 2006, A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study., J Child Adolesc Psychopharmacol
Angyal N et al., 2018, Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients., Prog Neuropsychopharmacol Biol Psychiatry
Kim BN et al., 2013, Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder., J Clin Psychopharmacol
Sandoval et al., 2001, Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model., J. Neurosci.
Yang et al., 2004, Association of norepinephrine transporter gene with methylphenidate response., J Am Acad Child Adolesc Psychiatry
Williard et al., 2007, Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity., Behav Pharmacol
Chuhan et al., 2006, Impairment of single-trial memory formation by oral methylphenidate in the rat., Neurobiol Learn Mem
Hong SB et al., 2012, Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?, J Child Adolesc Psychopharmacol
Gray et al., 2007, Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress., J. Neurosci.
Levy F et al., 2013, Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder., J Child Adolesc Psychopharmacol
Kim SW et al., 2013, ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD., J Clin Psychopharmacol
Stehouwer et al., 2006, Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography., J. Med. Chem.
Elangovan et al., 1996, Neurohormonal and behavioral response to methylphenidate in cocaine abstinence., Psychiatry Res
Weizman et al., 1987, Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity., Life Sci.
DeVane et al., 2000, Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers., J Clin Psychopharmacol
Song J et al., 2014, Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder., Clin Neuropharmacol
Labbe A et al., 2012, Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD., Am J Med Genet B Neuropsychiatr Genet
Bruxel EM et al., 2015, LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study., Genes Brain Behav
Arcos-Burgos M et al., 2010, A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication., Mol Psychiatry
Choudhry Z et al., 2012, LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy., J Child Psychol Psychiatry
Kim JI et al., 2017, Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder., J Psychopharmacol
Nemoda Z et al., 2009, Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD., Neuropharmacology
McCracken JT et al., 2014, Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders., Pharmacogenomics J
Markowitz JS et al., 2009, The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor., Pharmazie

METHYLPHENIDATE ADGRL3

Interaction Score: 4.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25229170 29230023 22851411 25989180 20157310 22486528

Sources:
PharmGKB
METHYLPHENIDATE OPCML

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ZNF134

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE NFIB

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ESYT2

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE PURA

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ZNF565

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE CHURC1

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ZDHHC7

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ARHGEF28

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ARHGAP12

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE SENP3

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ZNF211

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE PEBP4

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE WRB

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE FARP2

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE FXR2

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE TRIB3

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE CORO7

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE CMTM8

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE PIGM

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE CDH23

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ELP5

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE PDIA2

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE RRP7A

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE SPSB2

Interaction Score: 1.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ETFDH

Interaction Score: 1.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE GGH

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE ALDH1L1

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHYLPHENIDATE SLC6A3

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Dopamine transporter inhibitor

Direct Interaction yes

Trial Name Daytrana

PMIDs:
10414438 15572278 10199939 15303308 10403500 10025684 9537821 12699766 15827573 11752352 10037500 16806100 18698001 17201613

Sources:
NCI TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
METHYLPHENIDATE COMT

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29230023 23131881 24763183 18214865 18703939 22149470 24035255 21550019

Sources:
PharmGKB
METHYLPHENIDATE SLC6A2

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name methylphenidate HCl,Ritalin LA

Trial Name methylphenidate HCl,Metadate CD, Equasym

Novel drug target Established target

PMIDs:
29374517 23609393 29230023 11160413 15322419 17218796 9537821 16246598 23083021 16806100 17611273 18698001 17201613

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology
METHYLPHENIDATE TH

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26810137

Sources:
PharmGKB
METHYLPHENIDATE ARSA

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE PRL

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9122287 3035307

Sources:
NCI
METHYLPHENIDATE CES1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19733552

Sources:
PharmGKB
METHYLPHENIDATE SLC6A4

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name methylphenidate HCl,Concerta

Novel drug target Established target

Trial Name methylphenidate HCl,Metadate CD, Equasym

PMIDs:
10414438 10199939 17154506

Sources:
TEND TdgClinicalTrial
METHYLPHENIDATE GRIN2B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27624150

Sources:
PharmGKB
METHYLPHENIDATE HTR1A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19322953 17201613

Sources:
DrugBank
METHYLPHENIDATE DRD3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23856854

Sources:
PharmGKB
METHYLPHENIDATE NAT1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Norepinephrine transporter inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
METHYLPHENIDATE DRD1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23952191

Sources:
PharmGKB
METHYLPHENIDATE HTT

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29382897

Sources:
PharmGKB
METHYLPHENIDATE DRD2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26810137

Sources:
PharmGKB
METHYLPHENIDATE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23771192

Sources:
PharmGKB
METHYLPHENIDATE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10831022

Sources:
NCI

DrugBank: DB00422

Version: 5.1.7

Alternate Names:

Quillivant XR Drug Brand

METHYLPHENIDATE DrugBank Drug Name

113-45-1 CAS Number

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Izenwasser et al., 1999, Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine., Eur. J. Pharmacol.

Dresel et al., 1999, In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates., Eur J Nucl Med

Viggiano et al., 2004, Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling., Neural Plast.

TEND: METHYLPHENIDATE
- Version: 01-August-2011
Alternate Names:

METHYLPHENIDATE Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class central nervous system stimulants

Publications:
TdgClinicalTrial: METHYLPHENIDATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of ADHD

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: METHYLPHENIDATE

Version: 14-September-2017

Alternate Names:

C646 NCI drug code

Drug Info:

Publications:

DeVane et al., 2000, Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers., J Clin Psychopharmacol

Elangovan et al., 1996, Neurohormonal and behavioral response to methylphenidate in cocaine abstinence., Psychiatry Res

Weizman et al., 1987, Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity., Life Sci.

PharmGKB: methylphenidate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Pagerols M et al., 2017, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder., Pharmacogenomics J

Pagerols M et al., 2018, Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder., Sci Rep

Song J et al., 2014, Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder., Clin Neuropharmacol

TTD: Methylphenidate
- Version: 2020.06.01
Alternate Names:

D02PPN TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103810
- Version: 29-September-2020
Alternate Names:

METHYLPHENIDATE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL796
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL796
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Dopamine transporter inhibitor
Direct Interaction	yes
Trial Name	Daytrana

Trial Name	methylphenidate HCl,Ritalin LA
Trial Name	methylphenidate HCl,Metadate CD, Equasym
Novel drug target	Established target

Trial Name	methylphenidate HCl,Concerta
Novel drug target	Established target
Trial Name	methylphenidate HCl,Metadate CD, Equasym

Direct Interaction	yes
Mechanism of Interaction	Norepinephrine transporter inhibitor

Quillivant XR	Drug Brand
METHYLPHENIDATE	DrugBank Drug Name
113-45-1	CAS Number

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

METHYLPHENIDATE Drug Record

METHYLPHENIDATE chembl:CHEMBL796 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25229170 29230023 22851411 25989180 20157310 22486528

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29382897

Interaction Types & Directionality:

n/a

PMIDs:
25229170 29230023 22851411 25989180 20157310 22486528

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29382897